Mott K, et al. - Researchers sought to determine the prevalence of antidiabetic drugs (ADDs) use during pregnancy among women in the Mini-Sentinel Distributed Database (MSDD) who delivered a liveborn infant. From 2001 to 2013, they identified 1.9 million pregnancies in the MSDD that resulted in a live birth. Among these, ADD exposure was reported in 4.4%. Preexisting diabetes was reported in 15,606 pregnancies (0.8%); of these, 92.8% were also exposed during the pregnancy period. Insulin was identified to be the most commonly used product in these pregnancies (75.6% of pregnancies). In contrast, glyburide and insulin were the most commonly used products in pregnancies of women without prior ADD use; most of these users were diagnosed with gestational diabetes. The findings underscore the significance of continuing surveillance of ADD utilization patterns and analyzing the safety and effectiveness of these products in pregnancy.